Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015

Glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use among adults with diabetes mellitus by cardiovascular-kidney disease risk: National Health and Nutrition Examination Surveys, 2015–2020

Published:2024-03 Issue: Volume:17 Page:100624
ISSN:2666-6677
Container-title:American Journal of Preventive Cardiology
language:en
Short-container-title:American Journal of Preventive Cardiology

Author:

Jacobs Joshua A.^ORCID,Zheutlin Alexander R.,Derington Catherine G.,King Jordan B.,Pandey Ambarish,Bress Adam P.

Publisher

Elsevier BV

Subject

General Medicine

Reference20 articles.

1. Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum: Insights From the UK Biobank;Honigberg;J Am Coll Cardiol,2021

2. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023;ElSayed;Diabetes Care,2023

3. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee;Das;J Am Coll Cardiol,2020

4. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease;Rossing;Nephrol Dial Transplant,2023

5. Novo Ends Semaglutide Kidney Study Early Due to Strong Efficacy Signals. BioSpace. Accessed November 2, 2023. https://www.biospace.com/article/novo-ends-ozempic-study-early-due-to-strong-signals-of-efficacy/.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD);Fundamental & Clinical Pharmacology;2024-06-24